Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
|
|
- Whitney Kennedy
- 5 years ago
- Views:
Transcription
1 Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
2 «Δηλώνω ότι έχω λάβει τιμητική αμοιβή από την Pfizer Hellas» «Οι απόψεις που εκφράζονται σε αυτή την παρουσίαση ανήκουν στον ομιλητή και δεν εκφράζουν απαραίτητα τις απόψεις της εταιρείας. Για όλα τα φαρμακευτικά προϊόντα που αναφέρονται παρακαλείσθε να συμβουλεύεσθε τις εγκεκριμένες Περιλήψεις Χαρακτηριστικών των Προϊόντων».
3 RCTs vs real world data
4 Randomised clinical trials (RCTs) vs real-world data (RWD) RCT RCTs are randomised clinical trials conducted to test the safety and efficacy of healthcare products or services under carefully controlled conditions RWD RWD study is observational in nature and generally uses data from actual practice settings to perform analyses on comparative effectiveness, comparative costs, quality of life and signal detection, among others RCT compared with RWD? May include a broader and more heterogeneous patient population Generate data within the routine healthcare system Can address research questions that require larger patient numbers and long follow-up periods Can address research questions that cannot be studied by experiments for ethical or feasibility reasons RWD complements and augments RCT data 1. Garrison et al. Value Health. 2007;10: ; 2. Annemans et al. ISPOR Connections Available at: 4
5
6 maximizing the use of real world evidence Journal of Multidisciplinary Healthcare 2018:
7 ARISTOTLE: Study design and objectives 1 Event Driven* Apixaban 5.0 mg oral BD Patient Population 2 Aged 18 years Patients with NVAF and 1 risk factors for stroke Randomised, double-blind, double-dummy (2.5 mg oral BD in select patients [4.7%]) Warfarin (adjusted to an INR of2 3) The primary objective of the trial was to determine if apixaban was non-inferior to warfarin for the prevention ofstroke and systemic embolism. If non-inferiority was met, the following endpoints were tested for superiority 1,3 Stroke or systemic embolism (primary efficacy endpoint) ISTH major bleeding (primary safety endpoint) Death due to any cause (key secondary endpoint) *448 primary study events were needed. 2 of the following: age 80 years, weight 60 kg, serum creatinine level 1.5 mg/dl 1. Granger et al. N Engl J Med 2011;365: Lopes et al. Am Heart J 2010;159: Apixaban SmPC
8 Event rate (% / year) Apixaban is the only oral anticoagulant to demonstrate superiority vs. warfarin in all of the following 3 outcomes Superior stroke/systemic embolism prevention 21% RRR p=0.01 Superior profile in reducing major bleeding 31% RRR p<0.001 Superior reduction in all-cause mortality 11% RRR p= % 265/ % 212/ % 462/ % 327/ % 669/ % 603/9120 Primary efficacy endpoint Primary safety endpoint Key secondary endpoint Median duration of follow-up 1.8 years Figure created from data in Grangeret al. N Engl J Med 2011;365: Apixaban Warfarin (target INR )
9 Primary efficacy results for apixaban were consistent across major subgroups in ARISTOTLE Characteristics No. of patients Apixaban Warfarin Hazard Ratio (95% CI) No. of events (%/yr) All patients 18, (1.27) 265 (1.60) P value for interaction Prior warfarin/vka 0.39 Yes 10, (1.1) 138 (1.5) No 7, (1.5) 127 (1.8) Age 0.12 < 65 yrs 5, (1.0) 44 (0.9) 65 to < 75 yrs 7, (1.3) 112 (1.7) 75 yrs 5, (1.6) 109 (2.2) Sex 0.60 Male 11, (1.2) 160 (1.5) Female 6, (1.4) 105 (1.8) Weight kg 1, (2.0) 52 (3.2) > 60 kg 16, (1.2) 212 (1.4) Type of AF 0.70 Permanent/Persistent 15, (1.4) 235 (1.7) Paroxysmal 2, (0.8) 30 (1.1) Prior stroke or TIA 0.71 Yes 3, (2.5) 98 (3.2) No 14, (1.0) 167 (1.2) Diabetes mellitus 0.71 Yes 4, (1.4) 75 (1.9) No 13, (1.2) 190 (1.5) Primary efficacy endpoint: stroke or systemic embolism Apixaban better Warfarin better Adapted from Granger et al. N Engl J Med2011;365:
10 Primary efficacy results for apixaban were consistent across major subgroups in ARISTOTLE (cont) Characteristics No. of patients Apixaban Warfarin Hazard Ratio (95% CI) No. of events (%/yr) All patients 18, (1.27) 265 (1.60) P value for interaction Heart failure 0.50 Yes 5, (1.4) 79 (1.6) No 12, (1.2) 186 (1.6) CHADS 2 score , (0.7) 51 (0.9) 2 6, (1.2) 82 (1.4) 3 5, (1.9) 132 (2.8) Level of renal impairment 0.72 Severe or Moderate 3, (2.1) 69 (2.7) Mild 7, (1.2) 116 (1.7) No impairment 7, (1.0) 79 (1.1) Apixaban dose mg BID or placebo (1.7) 22 (3.3) 5 mg BID or placebo 17, (1.3) 243 (1.5) Geographic region 0.44 North America 4, (1.0) 56 (1.3) Latin America 3, (1.4) 52 (1.8) Europe 7, (1.1) 77 (1.1) Asian Pacific 2, (2.0) 80 (3.1) ASA use at randomisation 0.44 Yes 5, (1.3) 94 (1.9) No 12, (1.2) 171 (1.5) Primary efficacy endpoint: stroke or systemic embolism Apixaban better Warfarin better Adapted from Granger et al. N Engl J Med2011;365:
11 Relative to warfarin, apixaban was associated with a 33% lower major bleeding risk, Relative to rivaroxaban, apixaban was associated with a 48% lower risk of major bleeding risk. Apixaban was associated with a lower risk of major gastrointestinal bleeding than dabigatran. J Manag Care Spec Pharm. 2017;23(9):968-78
12 Among Japanese patients with NVAF, treatment with apixaban 5/2.5mg BID was associated with a significantly lower risk of major bleeding as well as any bleeding when compared to warfarin. Treatment with dabigatran 150/110mg BID or rivaroxaban 15/10mg QD was associated with a significantly lower risk of major bleeding, but not with a lower risk of any bleeding, compared to warfarin CURRENT MEDICAL RESEARCH AND OPINION, 2017 VOL. 33, NO. 11,
13 24 studies /retrospective analyses of administrative claims databases and patient registries half were based in the United States Apixaban showed a significantly lower risk of MB versus warfarin in all eight included studies. CURRENT MEDICAL RESEARCH AND OPINION, 2017 VOL. 33, NO. 9,
14 Apixaban vs Dabigatran Seven studies compared apixaban with dabigatran. Six studies reported that apixaban was associated with a numerically lower risk of MB compared to dabigatran no statistical significance in five of the studies. CURRENT MEDICAL RESEARCH AND OPINION, 2017 VOL. 33, NO. 9,
15 Apixaban vs Rivaroxaban All studies reported that apixaban was associated with a significantly lower risk of MB compared to rivaroxaban (HR: ; range of 95% CIs: ). Non-industry-sponsored studies reported a larger treatment effect for this comparison compared to industry-sponsored studies. CURRENT MEDICAL RESEARCH AND OPINION, 2017 VOL. 33, NO. 9,
16 Newly initiated on apixaban or warfarin meeting selection criteria N=18,591 Apixaban n=4,332 Warfarin n=14,259 Following propensity-score matching, stratified by exposure status 4,083 apixaban and 4,083 warfarin users were identified *PY=Patient-years Characteristics of included patients (matched cohorts) Parameter Apixaban (n=4,083) 2,125 PYs* Warfarin (n=4,083) 1,951 PYs* Age in years, mean (SD) (11.32) (11.25) Male, % CHADS 2 score, 180 day; mean (SD) CHA 2 DS 2 -VASc score, 180 day; mean (SD) HAS-BLED Score, 180 day; mean (SD) 1.93 (1.07) 1.92 (1.07) 3.47 (1.38) 3.47 (1.35) 1.65 (0.69) 1.66 (0.72) Reduced dose, % 15.5 NA
17 Apixaban was associated with a significant* 62% reduction in ICH vs. warfarin 13% non-significant increase in ischemic stroke vs. warfarin Non-significant 37% reduction in the combined endpoint of ICH and ischemic stroke vs. warfarin Apixaban Warfarin HR (95% CI) Rate (%/year) Rate (%/year) apixaban vs. warfarin HR (95% CI) apixaban vs. warfarin ICH ( ) Ischemic stroke ( ) Combined ( ) *p< Favors Favors apixaban warfarin
18 similar effectiveness of apixaban in stroke or TE prevention in the settings of real-world studies stroke Apixaban was safer than warfarin in the risks of major bleeding major bleeding Am J Cardiol 2017;120:
19 similar effectiveness for stroke or TE prevention and major bleeding when compared with dabigatran Am J Cardiol 2017;120:
20 similar effectiveness for stroke or TE prevention when compared with rivaroxaban A lower risk of major bleeding was seen in real-world studies when apixaban was compared with rivaroxaban Am J Cardiol 2017;120:
21 Three Danish nationwide databases, August 2011 to October patients No significant difference was found between NOACs and warfarin for ischaemic stroke. The risks of death, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran compared with warfarin. BMJ 2016;353:i3189
22
23 Apixaban vs VKAs for efficacy outcomes 3 studies that included patients Similar risk of ischemic stroke compared with VKAs (HR, 0.95; 95% CI, one study of patients Similar risk of ischemic stroke/systemic embolism compared with VKAs (HR, 1.07; 95% CI, ) Stroke. 2017;48:
24 Apixaban vs VKAs for intracranial hemorrhage 4 pooled studies that included patients apixaban was associated with lower risk for intracranial hemorrhage (HR, 0.45; 95% CI, ) Similar with Aristotle results Stroke. 2017;48:
25 Apixaban vs VKAs for major hemorrhage. 4 studies that included patients apixaban was associated with lower risk for major hemorrhage in (HR, 0.55; 95% CI, ) 31% reduction in ARISTOTLE trial Stroke. 2017;48:
26 Apixaban vs VKAs for gastrointestinal hemorrhage 2 studies that included patients lower risk for gastrointestinal hemorrhage in (HR, 0.63; 95% CI, ) In RE-LY, the dabigatran 150 mg arm had a 48% increased risk of gastrointestinal hemorrhage that was not present with the 110 mg dose 5 In the ROCKET-AF, this risk for rivaroxaban was increased by 46% as compared with warfarin In ARISTOTLE a non signification risk reduction of 11% was found with apixaban
27 Apixaban vs VKAs for mortality apixaban had lower mortality compared with VKAs in the ARISTOTLES trial apixaban was associated with a significant 11% reduction of mortality Stroke. 2017;48:
28 Retrospective study four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, Thromb Haemost 2017; 117:
29 Cumulative incidence of stroke/ systemic embolism and major bleeding Compared to warfarin, apixaban was associated with a 33 % lower risk of stroke/se (hazard ratio [HR]: 0.67, 95 % confidence interval [CI]: , p<0.001) within one year of treatment initiation Compared to warfarin, apixaban use was associated with a 40 % lower risk of major bleeding (HR: 0.60, 95 % CI: , p<0.001 within one year of treatment initiation) Thromb Haemost 2017; 117:
30 Hazard ratio of stroke/se and major bleeding for propensity score matched apixaban and warfarin patient Thromb Haemost 2017; 117:
31 stroke/se Subgroup analyses Major bleeding Consistently lower risks of stroke/se and major bleeding associated with apixaban as compared to warfarin treatment Thromb Haemost 2017; 117:
32 a total of patients treated with apixaban 16 studies PubMed and Scopus databases Stroke. 2018;49:98-106
33 Apixaban vs Warfarin for stroke no significant difference was found between apixaban and warfarin, both in the regular and reduced dose subgroups. Stroke. 2018;49:98-106
34 Apixaban vs Warfarin for hemorrhagic stroke hemorrhagic stroke risk was significantly reduced in apixaban treated patients (36% relative risk reduction [RRR]; P=0.0003), especially for the regular dose group Stroke. 2018;49:98-106
35 Apixaban vs Warfarin for major bleeding Compared with warfarin, major bleeding risk was significantly lower for patients treated with apixaban (OR, 0.62; 95% CI, ), with consistency for regular and low dose subgroups Stroke. 2018;49:98-106
36 Apixaban vs Warfarin for ICH Stroke. 2018;49: Risk reduction with apixaban was even greater when considering ICH (46% RRR; P< ) or GIB (OR, 0.63; 95% CI, ; P< ) compared with warfarin
37 Apixaban vs Dabigatran for stroke/ any thromboembolic event nonsignificant differences between apixaban and dabigatran in risk of any thromboembolic event (P=0.30) No difference was seen for stroke risk Stroke. 2018;49:98-106
38 Apixaban vs Dabigatran for major bleeding Major bleeding risk was significantly lower in apixaban patients compared with dabigatran ones (35% RRR; P< ) even though only 1 study was included in the reduced dose subgroup Stroke. 2018;49:98-106
39 Stroke. 2018;49: patients prescribed apixaban had a significantly lower risk for GIB (57% RRR; P< ) and any bleeding (31% RRR; P< )
40 Apixaban vs Dabigatran for intracranial hemorrhage/all cause death no difference was found for ICH and all-cause death between apixaban and dabigatran Stroke. 2018;49:98-106
41 Apixaban vs Rivaroxaban for major bleeding and ICH The risk of major bleeding was significantly lower in patients treated with apixaban compared with rivaroxaban (46% RRR; P< ), consistent with doses subgroups There was a significant risk reduction in ICH (OR, 0.46; 95% CI, ) Stroke. 2018;49:98-106
42 There was a significant risk reduction in GIB for apixaban compared with rivaroxaban (64% RRR; P< ), as well as for any bleeding (OR, 0.56; 95% CI, Stroke. 2018;49:98-106
43 Stroke. 2018;49:98-106
44
45
46
47
48 Deitelzweig et al, ACC 2018
49 Deitelzweig et al, ACC 2018
50
51 rates of permanent drug discontinuation dabigatran 110 mg 20.7% dabigatran 150 mg 21.2% rivaroxaban 25.3% apixaban 17.9% edoxaban 30 mg 33.0% edoxaban 60 mg 34.4% Mayo Clin Proc. 2014;89(7):
52 adherence to anticoagulation continues to be a challenge J Am Heart Assoc. 2016;5:e003074
53 LIMITATIONS observational clinical data cannot establish a cause effect relationship between medication prescription and outcomes but only an association between the studied variables and should not be regarded as direct comparisons between NOACs. The size of study cohort, follow-up duration, NOAC prescribing patterns(eg,standard doses only), Type of analysis(eg,claims-based retrospective analysis), end point definition(s), method used to adjust for baseline differences (eg, propensity score matching)
54 CONCLUSIONS Real world data consistently confirm apixaban as a safe and effective option treatment in patients with nonvalvular atrial fibrillation Complementary, real world data supports the main conclusions of Aristotle trial compared with warfarin, the use of apixaban in real-life is associated with an overall similar effectiveness in reducing stroke/systemic embolism, and superiority regarding major bleeding, all cause mortality In absence of direct head-to-head comparator RCT for the NOACs, real world data indicate apixaban, as a safer option for patients needing anticoagulation in comparison with other NOACs.
55 apixaban could possibly represent an apropriate alternative for OAC therapy, balancing effectiveness and safety
Ασθενείς με Κολπική Μαρμαρυγή προς καρδιοανάταξη ή κατάλυση. Δεδομένα για την Απιξαμπάνη
Ασθενείς με Κολπική Μαρμαρυγή προς καρδιοανάταξη ή κατάλυση. Δεδομένα για την Απιξαμπάνη Παναγιώτης Ιωαννίδης Διευθυντής Τμήματος Καρδιακής Ηλεκτροφυσιολογίας & Βηματοδότησης Βιοκλινικής Αθηνών Δορυφορική
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationΕίναι τα δεδομένα από τον πραγματικό κόσμο σε συμφωνία με τα αποτελέσματα των τυχαιοποιημένων κλινικών δοκιμών?
Είναι τα δεδομένα από τον πραγματικό κόσμο σε συμφωνία με τα αποτελέσματα των τυχαιοποιημένων κλινικών δοκιμών? Δ. ΡΙΧΤΕΡ, MD, FESC, FAHA -Διευθυντής Καρδιολογικής Κλ. Ευρωκλινικής Αθηνών -Αντιπρόεδρος
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationΕπιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική;
2ο ΣΥΝΕΔΡΙΟ ΚΑΡΔΙΑΓΓΕΙΑΚΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΑΘΗΝΑ 2017 Επιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική; Κωνσταντίνος Π. Λέτσας, MD, FEHRA Β Καρδιολογική Κλινική
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAnti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone
Anti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone Doreen Tan Cardiology Specialist Pharmacist 2017.04.08 Navigation Map Atrial Fibrillation What s the fuss?
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationUse of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist?
Use of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist? Prof. Dan Atar, MD Dept. of Cardiology B Oslo University Hospital, Norway Vice-President of the ESC
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationRivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion
Rivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion Riccardo Cappato Arrhythmia and Electrophysiology Research Center, IRCCS Humanitas Research
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More information